Maravai LifeSciences announced the completion of its acquisition of Officinae Bio’s DNA and RNA business. This acquisition integrates Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities.
The combined expertise and novel technologies are expected to provide customers with comprehensive support for rapid progression through the mRNA sequence-optimization phase and into clinical testing and commercial manufacturing. Officinae Bio's proprietary digital platform is designed to accelerate the prototyping of mRNA drug candidates.
This acquisition also marks Maravai's initial entry into the European marketplace with a manufacturing footprint, which is anticipated to fuel growth across multiple product lines in the post-pandemic era. Davide De Lucrezia will continue to lead the Officinae Bio team as a business unit within Maravai’s Nucleic Acid Production segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.